Check SCREEN READER MODE to make this survey compatible with screen readers.
(ENG) VIS 2024 Survey to countries
Gavi's Vaccine Investment Strategy (VIS) 2024 Survey to Gavi-eligible countries
The Gavi Secretariat is launching this survey to gather input on country priorities to inform the development of the Vaccine Investment Strategy (VIS) 2024.
The VIS is Gavi’s evidence-based prioritization process for inclusion of new immunisation products into its portfolio. It takes place every 5 years and involves a review of new and under-used vaccines to determine those of highest importance to Gavi-supported countries and with the greatest need for financial or other catalytic support.
The results of the VIS inform the development of Gavi's strategy and replenishment. The VIS 2024 will lead to immunization investment decisions in June 2024 for potential introduction in Gavi’s next strategic period (6.0) from 2026-2030.
The perspectives of colleagues at country level are key to the VIS. Through this survey, we would like to hear from you and provide you with the opportunity to shape the early stages of the VIS 2024 prioritisation process.
In December 2020, due to the COVID-19 pandemic, the Gavi Alliance Board decided to pause the introduction of vaccines that had been approved in the VIS 2018 process; DTP-containing booster vaccines, hepatitis B birth dose, human rabies vaccines for post-exposure prophylaxis and RSV. The Gavi Secretariat is assessing the requirements for ‘unpausing’ these vaccines, including country demand, programmatic feasibility and plans. This survey also includes questions regarding your country’s plans regarding these vaccines if relevant.
This survey should not take more than 15 minutes to complete.
It will be available from 20 February to 5 March 2023.
Please feel free to forward the survey to colleagues in your team.
Please note that responses will be aggregated and that individual responses will be kept confidential.
If you have any questions, please reach out to: vis@gavi.org